Skip to content

Quetiapine prevention for postoperative delirium in cardiac surgery: a randomized controlled study

Quetiapine prevention for postoperative delirium in cardiac surgery: a randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180124007
Enrollment
100
Registered
2018-01-24
Start date
2018-01-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac disease Delirium Prevention Cardiac Quetiapine

Interventions

Oral Quetiapine 12.5 mg at bedtime on preoperative day and postoperative day 0&#44
1 (3 days) ,Oral placebo at bedtime on preoperative day and postoperative day 0&#44
1 (3 days)
Experimental Drug,Placebo Comparator Drug

Sponsors

Ramathibodi hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 55 yr or more Patients underwent cardiac surgery with cardiopulmonary bypass Written informed consent

Exclusion criteria

Exclusion criteria: Emergency surgery Patients with psychiatric disease or delirium Patients received cholinesterase inhibitors, levodopa and antipsychotic Patients with prolong QT Allergy to quetiapine Patients who were admitted in ICU or were intubated prior study.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative delirium at postoperative Day 0,1,2,3 CAM-ICU score

Secondary

MeasureTime frame
Duration of delirium at postoperative Day 0,1,2,3 days,Length of ICU stay at postoperative Day 0,1,2,3 days,Length of hospital stay at postoperative Day 0,1,2,3 days,Complication at postoperative Day 0,1,2,3 number count

Countries

Thailand

Contacts

Public ContactNarut Ruananukun

Ramathibodi Hospital

aek_narut@hotmail.com+66815954599

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026